Please ensure Javascript is enabled for purposes of website accessibility

Why Clovis Oncology Stock Marched Higher in April

By George Budwell – May 11, 2020 at 11:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Clovis Oncology's stock reversed course last month.

What happened

Shares of small-cap cancer company Clovis Oncology (CLVS 0.00%) gained a whopping 33.7% over the course of April, according to data from S&P Global Market Intelligence. Clovis' stock regained its footing last month for two overarching reasons. 

So what

First and foremost, Clovis' stock lost a noteworthy 15% of its value during March in response to the COVID-19 pandemic. As the company didn't announce any major hiccups in its commercial operations stemming from the public health crisis in April, bargain hunters apparently felt comfortable buying shares in the wake of this double-digit decline.

A woman wearing slacks, a shirt, and a head scarf and staring out of a window.

Image Source: Getty Images.

Secondly, Clovis is set to receive the Food and Drug Administration's ruling on the label expansion for Rubraca as a treatment for advanced BRCA-mutant prostate cancer on May 15. As this indication could boost Rubraca's annual sales by several hundred million, and quite possibly transform the company into a cash-flow-positive operation within a few short years, it's not surprising to see Clovis' stock perk up heading into this long-awaited regulatory decision. 

Now what

Can Clovis' stock head even higher in the days and weeks ahead? It's hard to tell. A positive regulatory nod for Rubraca in advanced BRCA-mutant  prostate cancer would certainly help matters, but the company still needs to address its unsightly cash burn rate in order to win over long-term investors. In the most recent quarter, for example, Clovis reported a net loss of $99.3 million. That kind of burn rate is hard to justify for a company with a market cap under $700 million. In short, this biotech stock may struggle to print new highs until the company becomes cash flow positive on a consistent basis.   

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clovis Oncology, Inc. Stock Quote
Clovis Oncology, Inc.
CLVS
$1.05 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.